Bowel Disease
Conditions
Brief summary
Patients who require screening colonoscopy will receive an intraluminal spraying of NPO-13 per contraction region of large bowel up to fifth times during the colonoscopy. The efficacy of NPO-13 will be evaluated based on the proportion of the splayed region with no contraction after NPO-13 dosage (primary outcome measure). The colonic spasm will be assessed by an independent committee using recorded video images. The safety of NPO-13 will be evaluated based on adverse events and adverse drug reactions (ADRs) observed between administration and seven days after administration.
Interventions
DRUGNPO-13
Sponsors
Nihon Pharmaceutical Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Inpatients or outpatients of either sex who visit medical institutions for treatment or follow-up of confirmed or suspected colonic disease (symptoms) and meet the criteria (1) and (2) below will be enrolled in the study. Patients have to provide written informed consent for voluntary participation in the study. 1. Patients who need colonoscopy 2. Patients who are older than 20 years at the time of consent
Exclusion criteria
1. Patients with a history of abdominal surgical treatment (including the laparoscopic surgery) including the gynecology operation 2. Patients with contraindication to colonoscopy including the paralytic ileus 3. Patients with a history of shock or hypersensitivity to l-menthol or peppermint oil (mint oil) 4. Patient with contraindication to bowel cleansing preparation 5. Patients on cancer treatment (chemotherapy or radiotherapy) 6. Patients who need sedative colonoscopy 7. Patients who receives a therapeutic colonoscopy 8. Pregnant or lactating women, women of childbearing potential, or women who plan to become pregnant during the study 9. Patients who have received other investigational drugs within four months before consent or who are participating in other clinical studies 10. Patients who have been exposed to NPO-13 11. Patients otherwise ineligible for participation in the study in the investigator's or subinvestigator's opinion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of the splayed region with no contraction after NPO-13 dosage | 3 min |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of the splayed region with an onset of action | 3 min |
| The proportion of patients with no contraction in all the sprayed regions | 3 min |
| The proportion of patients with no contraction in one or more the sprayed region | 3 min |
| Change in colonic contraction | 3 min |
| Adverse events and ADRs observed between administration and 7 ± 3 days after administration | up to 10 days |
Countries
Japan
Outcome results
None listed